CS3003

CS3003 is an investigational **small-molecule, selective histone deacetylase 6 inhibitor** being developed by **CStone Pharmaceuticals** for cancer treatment. It is designed to inhibit **HDAC6**, disrupt HDAC6-mediated processing of misfolded proteins, increase intracellular stress, and promote tumor-cell apoptosis, supporting its development as an **epigenetic modulator** and targeted antineoplastic agent. Publicly described development has included a **Phase I** study in **advanced solid tumors** and **relapsed or refractory multiple myeloma**, and the program has also been noted as having potential for combination use with **PD-(L)1 antibodies** in solid tumors.